Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials

International Journal of Cancer

Volumn 137, Issue 2, 2015, Pages 409-419

  Ma, Wang ^a   Xu, Mingxin ^b   Liu, Yiqian ^c   Liu, Hao ^d   Huang, Jiale ^b   Zhu, Yanjie ^b   Ji, Li Juan ^e   Qi, Xiaolong ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Second People's Hospital of Huai'an   (China)

Author keywords

adverse events; EGFR; non small cell lung cancer; randomized clinical trial; targeted therapy; VEGF

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CONSTIPATION; COUGHING; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRY SKIN; DYSGEUSIA; DYSPNEA; ENZYME INHIBITION; FATIGUE; HEMOPTYSIS; HUMAN; HYPERTENSION; INSOMNIA; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; DRUG EFFECTS; LUNG NEOPLASMS; META ANALYSIS; METABOLISM; OUTCOME ASSESSMENT; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIARRHEA; EXANTHEMA; FATIGUE; HUMANS; LUNG NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PIPERIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84929295755     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29377     Document Type: Article

References (49)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. Cancer 2014; 64: 9-29.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute. http://seer.cancer.gov/csr/1975-2011/.
3. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
5. Ciardiello F, Tortora G,. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
6. Stella GM, Scabini R, Inghilleri S, et al. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. J Cancer Res Clin Oncol 2013; 139: 1327-35.
7. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29: 2121-7.
8. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25: 587-95.
9. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25: 4743-50.
10. Gridelli C, Morgillo F, Favaretto A, et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. Ann Oncol 2011; 22: 1528-34.
11. Ciuleanu T, Tsai CM, Tsao CJ, et al. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer 2013; 82: 276-81.
12. Spigel DR, Burris HA, III, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2582-9.
13. Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012; 30: 2070-8.
14. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 1059-66.
15. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009; 27: 2523-9.
16. Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1846-54.
17. Herbst RS,. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11: 619-26.
18. Groen HJ, Socinski MA, Grossi F, et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol 2013; 24: 2382-9.
19. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15: 1236-44.
20. Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30: 1114-21.
21. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 5407-15.
22. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007; 25: 4270-7.
23. de Boer RH, Arrieta O, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29: 1067-74.
24. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013; 31: 3004-11.
25. Correale P, Remondo C, Carbone SF, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2010; 9: 685-93.
26. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-91.
27. Mir O, Boudou-Rouquette P, Giroux J, et al. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. Lung Cancer 2012; 77: 104-9.
28. Mok TS, Hsia TC, Tsai CM, et al. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol 2011; 7: 4-12.
29. Raez LE, Santos ES, Webb RT, et al. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC). Cancer Chemother Pharmacol 2013; 72: 1103-10.
30. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27: 5255-61.
31. Stevenson JP, Langer CJ, Somer RA, et al. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer 2012; 118: 5580-7.
32. Dudek AZ, Kumar P. H, Thaw SS, et al. Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC. Am J Clin Oncol 2014; 37: 140-3.
33. Gordon MS, Cunningham D,. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69: 25-33.
34. Package Insert. Avastin (bevacizumab) 2006. San Francisco: CG Inc., 2008.
35. Boehm S, Rothermundt C, Hess D, et al. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly-a mini-review. Gerontology 2010; 56: 303-9.
36. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1835-42.
37. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010; 28: 49-55.
38. O'Keefe E, Battin T, Payne R, Jr., Epidermal growth factor receptor in human epidermal cells: direct demonstration in cultured cells. J Investig Dermatol 1982; 78: 482-7.
39. Harandi A, Zaidi AS, Stocker AM, et al. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol 2009; 2009: 567486.
40. Hirsh V,. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol (Toronto, Ont) 2011; 18: 126-38.
41. Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012; 78: 8-15.
42. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
43. Saltz LB, Meropol NJ, Loehrer PJ, Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.
44. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8: 303-6.
45. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-14.
46. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
47. Tian W, Ding W, Kim S, et al. Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis. PLoS One 2013; 8: e67929.
48. Barni S, Cabiddu M, Guarneri P, et al. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012; 17: 715-24.
49. Zhang X, Li Y, Li H, et al. Combined EGFR and VEGFR versus single EGFR signaling pathways inhibition therapy for NSCLC: a systematic review and meta-analysis. PLoS One 2012; 7: e40178.